Long-Term Safety and Efficacy of Picotamide,a Dual-Action Antithromboxane Agent,in Diabetic Patients with Carotid Atherosclerosis: A 6-Year Follow-Up Study

Abstract

In a controlled, randomized, 6-year trial the safety and efficacy of picotamide, a dual-action antithromboxane agent, were assessed in 50 patients with type 2 diabetes mellitus at increased risk of thrombotic vascular events. The patients were randomized to two groups of equal size and received 900 mg picotamide daily or placebo. After phase I (double-blind; years 1–2), patients receiving placebo were treated, if necessary, with antiplatelet drugs (aspirin, ticlopidine) while members of the other group continued to receive 600 mg picotamide daily. In the course of the study 21 vascular events occurred: 16 in the group receiving placebo (fatal myocardial infarction, n = 7; non-fatal stroke, n = 3) and five in the group receiving drug (fatal myocardial infarction, n = 2) (P < 0.005; Fisher's exact test). One patient (placebo group) died of malignant disease. During the initial double-blind phase a total of nine vascular events was observed (six and three in the groups receiving placebo and drug, respectively). Picotamide treatment was well tolerated and no major side-effects were observed during the study periods.

Keywords

PICOTAMIDE THROMBOXANE ANTAGONISTS VASCULAR DISEASE DIABETICS PLATELET AGGREGATION

Get full access to this article

View all access options for this article.

References

Yudkin

: Coronary heart disease in diabetes mellitus: three new risk factors and unifying hypothesis. J Intern Med 1995; 238: 21–30.

Stamler

Vaccaro

Neaton

: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444.

Antiplatelet Trialists' Collaboration : Collaborative overview of randomised trials of antiplatelet therapy part 1. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.

Cimminiello

Milani

: Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events? Diabetologia 1996; 39: 1402–1404.

Colwell

Bingham

Abraira

: Veterans' Administration cooperative study group on antiplatelet agents in diabetic patients after amputation for gangrene. Effects of aspirin and dipyridamole on atherosclerotic vascular disease rates. Diabetes Care 1986; 9: 140–148.

Marwick

: Aspirin's role in prevention now official. JAMA 1997; 277: 701–702.

Duggan

Dobson

Johnson

: Peptic ulcer and non-steroidal anti-inflammatory agents. Gut 1986; 27: 929–933.

Modesti

Cecioni

Colella

: Binding kinetics and antiplatelet activities of picotamide, a thromboxane A₂ receptor antagonist. Br J Pharmacol 1994; 112: 81–86.

Milani

Longoni

Maderna

: Effects of Picotamide, an antiplatelet agent, on cardiovascular events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study. Br J Clin Pharmacol 1996; 42: 782–785.

10.

Balsano

Violo

the ADEP Group : Effects of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. Circulation 1993; 87: 1563–1569.

11.

Giustina

Bossoni

Cimino

: Picotamide, a dual TXB₂ synthetase inhibitor and TXB₂ receptor antagonist, reduces exercise-induced albuminuria in microalbuminuric patients with NIDDM. Diabetes 1993; 42: 178–182.

12.

Desenzani

Perini

Milani

: Long-term picotamide, a dual thromboxane inhibitor decreases both the urinary excretion of thromboxane B₂ an albumin in patients with type 2 diabetes. Diabetes 1997; 40: (Suppl 1): 2148.

13.

Cocozza

Picano

Oliviero

: Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution. Stroke 1995; 26: 597–601.

14.

Schneider

Sobel

: Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Clin Cardiol 1997; 20: 433–440.

15.

Lundberg

Stegmayr

Asplund

: Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med 1997; 241: 485–492.

16.

Daví

Gresele

Violi

: Diabetes mellitus, hypercholesterolemia and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Circulation 1997; 96: 69–75.

17.

Coté

Battista

Abrahamowicz

: Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. Ann Intern Med 1995; 123: 649–655.

18.

Violi

Longoni

Maderna

: Safety of picotamide, an antiplatelet agent, in an 18-month, double-blind, placebo-controlled, multicenter trial in 2304 patients with peripheral vascular disease. Curr Ther Res 1993; 54: 111–121.